All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Tarlatamab Yields OS Improvement in SCLC After Platinum Progression

April 11th 2025

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer

April 11th 2025

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

April 11th 2025

The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.

NK Cells Complexed With Bispecific Antibody Yield High Response Rates in Patients With Lymphoma

April 11th 2025

A phase 1 trial demonstrated that AFM13-NK cells are safe and highly effective in heavily pretreated patients with lymphomas.

PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

April 11th 2025

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX

April 10th 2025

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Social Determinants of Health Significantly Affect Some Psychoneurological Symptoms in Breast Cancer Survivors

April 10th 2025

Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.

A Mount Sinai Steering Committee Helps Merge Clinical Trials Into the SOC in Oncology

April 10th 2025

A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC

April 10th 2025

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC

April 10th 2025

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC

April 10th 2025

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan

April 10th 2025

A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

FDA Approves Larotrectinib for NTRK-Positive Solid Tumors

April 10th 2025

The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.

Roswell Park Reports Extraordinary Outcomes for Robot-Assisted Minimally Invasive Esophagectomy

April 10th 2025

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.

Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa

April 9th 2025

Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.

Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

April 9th 2025

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer

April 9th 2025

SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC

April 9th 2025

Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.